Metabolic syndrome and hypogonadism. Testosteron may protect the heart in type 2 diabetes mellitus

[1] Balkau B(1999)Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) Diabet Med 16 442-443

[2] Charles MA(2003)Use of metabolic markers to identify overweight individuals who are insulin resistant Ann Intern Me 139 802-809

[3] McLaughlin T(2008)European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age ans modifiable risk factors: the European Male Aging Study J Clin Endocrinol Metab 93 2737-2745

[4] Abbasi F(2009)Testosterone deficiency, insulin resistance and the metabolic syndrome Nat Rec Endocrinol 5 673-681

[5] Cheal J(2015)Testosteronmangel Dtsch Med Wochenschr 140 160-162

[6] Wu FC(2010)Testosteron und das metabolische Syndrom Urologe 49 47-50

[7] Tajar A(2014)Cardiovaskular risk associated with testosterone-boosting medications: a systematic review and meta-analysis Expert Opin Drug Saf 13 1327-1351

[8] Pye SR(2011)Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study) Diab Care 34 829-837

[9] Zitzmann M(2012)Testosterone Treatment and Mortality in Men with Low Testosterone Levels J Clin Endocrinol Metab 97 2050-2058

[10] Zitzmann M(2013)Association of testosterone therapy with mortality, myocardial infarction and stroke in men with low testosterone levels JAMA 310 1829-1836

[1] Balkau B(1999)Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) Diabet Med 16 442-443

[2] Charles MA(2003)Use of metabolic markers to identify overweight individuals who are insulin resistant Ann Intern Me 139 802-809

[3] McLaughlin T(2008)European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age ans modifiable risk factors: the European Male Aging Study J Clin Endocrinol Metab 93 2737-2745

[4] Abbasi F(2009)Testosterone deficiency, insulin resistance and the metabolic syndrome Nat Rec Endocrinol 5 673-681

[5] Cheal J(2015)Testosteronmangel Dtsch Med Wochenschr 140 160-162

[6] Wu FC(2010)Testosteron und das metabolische Syndrom Urologe 49 47-50

[7] Tajar A(2014)Cardiovaskular risk associated with testosterone-boosting medications: a systematic review and meta-analysis Expert Opin Drug Saf 13 1327-1351

[8] Pye SR(2011)Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study) Diab Care 34 829-837

[9] Zitzmann M(2012)Testosterone Treatment and Mortality in Men with Low Testosterone Levels J Clin Endocrinol Metab 97 2050-2058

[10] Zitzmann M(2013)Association of testosterone therapy with mortality, myocardial infarction and stroke in men with low testosterone levels JAMA 310 1829-1836